HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The sacral chordoma margin.

AbstractOBJECTIVE:
Aim of the manuscript is to discuss how to improve margins in sacral chordoma.
BACKGROUND:
Chordoma is a rare neoplasm, arising in half cases from the sacrum, with reported local failure in >50% after surgery.
METHODS:
A multidisciplinary meeting of the "Chordoma Global Consensus Group" was held in Milan in 2017, focusing on challenges in defining and achieving optimal margins in chordoma with respect to surgery, definitive particle radiation therapy (RT) and medical therapies. This review aims to report on the outcome of the consensus meeting and to provide a summary of the most recent evidence in this field. Possible new ways forward, including on-going international clinical studies, are discussed.
RESULTS:
En-bloc tumor-sacrum resection is the cornerstone of treatment of primary sacral chordoma, aiming to achieve negative microscopic margins. Radical definitive particle therapy seems to offer a similar outcome compared to surgery, although confirmation in comparative trials is lacking; besides there is still a certain degree of technical variability across institutions, corresponding to different fields of treatment and different tumor coverage. To address some of these questions, a prospective, randomized international study comparing surgery versus definitive high-dose RT is ongoing. Available data do not support the routine use of any medical therapy as (neo)adjuvant/cytoreductive treatment.
CONCLUSION:
Given the significant influence of margins status on local control in patients with primary localized sacral chordoma, the clear definition of adequate margins and a standard local approach across institutions for both surgery and particle RT is vital for improving the management of these patients.
AuthorsS Radaelli, P Fossati, S Stacchiotti, T Akiyama, J M Asencio, S Bandiera, A Boglione, P Boland, S Bolle, Ø Bruland, A Brunello, P Bruzzi, D Campanacci, F Cananzi, R Capanna, R Casadei, A Cordoba, C Court, A P Dei Tos, T F DeLaney, A De Paoli, T M De Pas, A Desai, L Di Brina, D M Donati, N Fabbri, M R Fiore, A Frezza, M Gambarotti, A Gasbarrini, P Georg, G Grignani, N Hindi, E B Hug, R Jones, A Kawai, A D Krol, F Le Grange, A Luzzati, G Marquina, J A Martin-Benlloch, K Mazzocco, F Navarria, P Navarria, P D Parchi, S Patel, E Pennacchioli, M G Petrongari, P Picci, R Pollock, L Porcu, V Quagliuolo, C Sangalli, S Scheipl, G M Scotto, M Spalek, T Steinmeier, B Timmermann, A Trama, M Uhl, C Valverde, P P Varga, R Verges, D C Weber, C Zoccali, P G Casali, J Sommer, A Gronchi
JournalEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (Eur J Surg Oncol) Vol. 46 Issue 8 Pg. 1415-1422 (08 2020) ISSN: 1532-2157 [Electronic] England
PMID32402509 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Topics
  • Chordoma (radiotherapy, surgery)
  • Humans
  • Margins of Excision
  • Proton Therapy (adverse effects)
  • Radiotherapy Dosage
  • Sacrum (surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: